Edwards Lifesciences (NYSE:EW) Stock Rating Upgraded by Wall Street Zen

Key Points

• Edwards Lifesciences was upgraded from a "buy" to a "strong-buy" rating by investment analysts at Wall Street Zen, indicating increased confidence in the stock.
• Royal Bank of Canada raised its price target on the stock from $85.00 to $89.00, while other analysts have set targets ranging from $81.00 to $100.00.
• Edwards Lifesciences reported better-than-expected Q2 earnings with $0.67 EPS and revenue of $1.53 billion, reflecting an 11.9% increase year-over-year.

Edwards Lifesciences (NYSE:EW - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating in a research report issued to clients and investors on Saturday.

A number of other equities research analysts also recently weighed in on the company. Wells Fargo & Company upped their target price on Edwards Lifesciences from $84.00 to $88.00 and gave the stock an "overweight" rating in a research report on Thursday, August 7th. Stifel Nicolaus upped their price target on Edwards Lifesciences from $90.00 to $95.00 and gave the company a "buy" rating in a report on Friday, July 25th. Truist Financial raised their price objective on Edwards Lifesciences from $81.00 to $82.00 and gave the stock a "hold" rating in a research note on Friday, July 25th. Morgan Stanley boosted their target price on Edwards Lifesciences from $75.00 to $81.00 and gave the stock an "equal weight" rating in a research report on Tuesday, July 15th. Finally, BTIG Research upgraded Edwards Lifesciences from a "neutral" rating to a "buy" rating and set a $100.00 price target for the company in a research report on Tuesday, July 29th. Three research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $85.90.

Edwards Lifesciences Stock Performance

EW traded down $0.24 during trading hours on Friday, hitting $80.98. The company's stock had a trading volume of 2,501,007 shares, compared to its average volume of 3,587,524. The company has a 50-day simple moving average of $78.71 and a 200 day simple moving average of $75.17. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $47.55 billion, a PE ratio of 11.65, a PEG ratio of 3.92 and a beta of 1.07. Edwards Lifesciences has a fifty-two week low of $64.00 and a fifty-two week high of $83.00.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.62 by $0.05. The company had revenue of $1.53 billion during the quarter, compared to analysts' expectations of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The company's revenue for the quarter was up 11.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.70 earnings per share. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. As a group, sell-side analysts expect that Edwards Lifesciences will post 2.45 EPS for the current year.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 4,114 shares of the stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $79.46, for a total value of $326,898.44. Following the completion of the sale, the vice president owned 22,002 shares in the company, valued at $1,748,278.92. This represents a 15.75% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Larry L. Wood sold 8,950 shares of the business's stock in a transaction on Monday, June 16th. The shares were sold at an average price of $75.23, for a total transaction of $673,308.50. Following the transaction, the insider owned 206,900 shares in the company, valued at approximately $15,565,087. This represents a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 22,014 shares of company stock worth $1,698,844. Company insiders own 1.29% of the company's stock.

Hedge Funds Weigh In On Edwards Lifesciences

Hedge funds have recently added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC lifted its stake in shares of Edwards Lifesciences by 0.5% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company's stock valued at $2,170,000 after purchasing an additional 145 shares during the last quarter. Alyeska Investment Group L.P. bought a new stake in shares of Edwards Lifesciences during the 4th quarter worth about $49,038,000. Dynamic Advisor Solutions LLC boosted its position in Edwards Lifesciences by 2.4% during the first quarter. Dynamic Advisor Solutions LLC now owns 15,506 shares of the medical research company's stock worth $1,124,000 after purchasing an additional 370 shares during the period. Wealth Enhancement Advisory Services LLC raised its position in shares of Edwards Lifesciences by 13.5% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 77,016 shares of the medical research company's stock valued at $5,582,000 after purchasing an additional 9,188 shares during the period. Finally, United Asset Strategies Inc. lifted its stake in shares of Edwards Lifesciences by 10.4% in the first quarter. United Asset Strategies Inc. now owns 185,571 shares of the medical research company's stock worth $13,450,000 after buying an additional 17,412 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company's stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.